[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612146":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":58,"collaborators":20,"id":60,"slug":20,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":20,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Nabiqasim Industries (Pvt) Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MASH targeted therapy","EXPERIMENTAL","MASH fibrosis stage 2 or 3",[13],"Drug: Resmetirom",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Resmetirom","1st FDA approved MASH therapy",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hussain B Abidi, MBBS, MBA, CRCP","CONTACT","+923322583236","MDR.hussainabidi@gmail.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":20,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Liver transplant center, Holy family hospital","RECRUITING","Rawalpindi","Punjab Province","Pakistan",{"type":35,"coordinates":36},"Point",[37,38],73.0479,33.59733,{"lat":38,"lon":37},[41,45,47,50,51,54,56],{"name":42,"role":24,"phone":43,"phoneExt":20,"email":44},"Shanila Akhter","+92 307 6738460","'shanilaakhter105@gmail.com'",{"name":46,"role":24,"phone":20,"phoneExt":20,"email":20},"Dr Anum Shakeel",{"name":48,"role":49,"phone":20,"phoneExt":20,"email":20},"Dr. Muhammad Umar","PRINCIPAL_INVESTIGATOR",{"name":46,"role":49,"phone":20,"phoneExt":20,"email":20},{"name":52,"role":53,"phone":20,"phoneExt":20,"email":20},"Dr. Bushra Khar","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":20,"phoneExt":20,"email":20},"Dr Sadia Khan",{"name":57,"role":53,"phone":20,"phoneExt":20,"email":20},"Dr Tayyab Sb.",{"type":59,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100612146",false,"NCT07249788","Resmiterom Efficacy & Safety in Patients With MASH","Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study","REZMASH","Inclusion Criteria:\n\n* • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)\n\n  * Clinical diagnosis of MASH using:\n\n    * LSM ≥ 8.5kpa And\u002For\n    * FAST score ≥0.67 And\u002For\n    * FibroScan CAP ≥ 275 dB\u002Fm And\u002For\n    * FIB-4 \\> 1.3\n\nExclusion Criteria:\n\n* • History of drug addiction and alcoholism\n\n  * Cirrhosis or decompensated liver disease\n  * Chronic viral hepatitis HBV, HCV)\n  * MACE including MI, Stroke, PE etc.\n  * Pregnant\u002Flactating women\n  * Concurrent use of other investigational drugs\n  * History of other liver diseases (viral, autoimmune, drug-induced, alcohol)\n  * Previous use of resmetirom in last 6 months\n  * Significant renal impairment (eGFR \\\u003C30)","ALL","18 Years","75 Years",{"count":71,"type":72},165,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.",[78],"MASH - Metabolic Dysfunction-Associated Steatohepatitis",[17,80,81,82],"MASH","Safety","Efficacy","2025-11-25",{"date":85,"type":86},"2025-12-03","ACTUAL",{"date":88,"type":86},"2025-10-17",{"date":90,"type":72},"2026-12-31",{"name":5,"class":6},1]